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ABSTRACT
Objective: SCN5A encodes alpha subunit of the major sodium channel (Nav1.5) in human cardiac tissue. Malfunction of this cardiac sodium 
channel is associated with a variety of cardiac arrhythmias and myocardial inherited diseases.
Methods: Fifty-three members from three families each diagnosed with long-QT syndrome type 3 (LQTS3), Brugada syndrome (BrS), or sick sinus syn-
drome (SSS) were included in this observational, cross-sectional study. In this study, we analyzed the sequences of coding region of the SCN5A gene.
Results: Eleven members of the LQTS family (39%) showed p.Gln1507-Lys1508-Pro1509del mutation, 8 of BrS family (50%) showed p.Arg222Ter 
nonsense mutation, and 5 of 9 SSS family members (55%) showed a novel p.Met1498Arg mutation in the SCN5A gene.
Conclusion: p.Gln1507-Lys1508-Pro1509del mutation, p.Arg222Ter nonsense mutation, and p.Met1498Arg in LQTS, BrS, and SSS, respectively, 
are reported for the first time in the Iranian population. Information regarding underlying genetic defects would be necessary for verifying 
certain clinically diagnosed arrhythmia types, carrier screening in affected families, and more precise therapy of the patients are required. 
(Anatol J Cardiol 2016; 16: 170-4)
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Genetic analysis of cardiac SCN5A Gene in Iranian patients with 
hereditary cardiac arrhythmias
Introduction
SCN5A encodes alpha subunit of the major sodium channel 
(Nav1.5) in human cardiac tissue. The channel is expressed in 
multiple tissues with similar structure. The gene is located on 
chromosome 3p21 with 28 exons and encodes a 227KDa alpha 
subunit (1). Malfunctioning of this cardiac sodium channel is 
associated with a variety of cardiac arrhythmic and myocardial 
inherited diseases, such as long-QT syndrome (LQTS) (type 3), 
syndrome of right precordial ST elevation [Brugada syndrome, 
(BrS)], cardiac conduction disease (CCD), sinus node dysfunc-
tion (SSS), atrial fibrillation (AF), atrial standstill, and dilated 
cardiomyopathy (2). The role of SCN5A mutations in each of 
these diseases is being investigated and new aspects are being 
discovered every day. Previous studies showed that 10%–30% of 
subjects with BrS carry a mutation in SCN5A, including mis-
sense mutations, nonsense mutations, and nucleotide deletions 
or insertions (3, 4). More than 100 SCN5A mutations are linked to 
BrS. Virtually all mutations that are heterologously expressed 
(<50%) lead to sodium channel loss of function (3). On the other 
hand, LQT-3 is linked to mutations in SCN5A, and covers approx-
imately 13% of all genotyped individuals with LQTS. Until now, 
more than 80 SCN5A mutations have been identified in patients 
with LQTS-3 and nearly 50% of them have been heterologously 
studied. Most of these mutations are missense mutations, and 
are found to cause sodium channel gain of function (3). Recently, 
a number of studies have linked genetic defects in ion channels, 
including human Nav1.5 (hNav1.5), to familial SSS. Until now, 14 
SCN5A mutations have been associated with this disease (5).
Variations in the SCN5A gene are associated with several 
other heart conditions; this includes familial heart block, an 
abnormality of the heart’s electrical system that increases the 
risk of syncope and sudden death (6, 7). The role of SCN5A 
mutations in diagnosis and risk stratification of the attributed 
syndromes is still a topic of debate. Furthermore, some muta-
tions in SCN5A are not associated with any sodium channel 
dysfunction (8).
In this study, 53 patients from three families clinically diag-
nosed with LQTS, BrS, and SSS were screened for SCN5A muta-
tions and three different mutations, including a novel one were 





The number of cases studied in the LQTS family was 28. The 
clinical criteria for LQTS diagnosis was the absence of intra- or 
inter-ventricular or atrio-ventricular conduction abnormalities (by 
demonstrating narrow QRS in standard 12-lead ECG); both mem-
bers with normal QTc interval and prolonged interval with inter-
pretable ECG, prolonged QTc was defined as more than 460 msec 
in females and 450 msec in males calculated with Bazett’s 
Formula [QTc=QT Interval/√(RR interval)] (Fig. 1); and exclusion of 
electrolyte abnormalities and coronary artery disease, which can 
mimic LQTS ECG pattern in patients with prolonged QTc interval.
BrS patients
Sixteen patients, belonging to a family diagnosed with BrS 
were included in this study. 
BrS-ECG is defined as ST segment elevation with type-1 
morphology >2 mm in at least 1 lead among the right precordial 
leads V1,V2, positioned in the 2nd, 3rd, or 4th intercostal space, 
occurring either spontaneously or following provocative drug 
test with intravenous administration of class I antiarrhythmic 
drugs (4) (Fig. 2). Other abnormalities mimicking BrS ECG pattern, 
including electrolyte abnormalities, coronary artery disease (by 
exercise stimulation test), and cardiac structural abnormalities 
(by normal echocardiography), were ruled out.
SSS patients
The inclusion criteria for the 9 selected patients from a fam-
ily diagnosed with SSS were: consumption of no drug that can 
mimic SSS such as beta blockers, exclusion of other abnormali-
ties mimicking SSS ECG pattern including electrolyte abnormali-
ties and coronary artery disease (by myocardial perfusion scan) 
(Fig. 3), and we finally defined SSS as either symptomatic sinus 
bradycardia of less than 40 beats per min or symptomatic sinus 
pause of more than 3 s in 48 h Holter monitoring, or symptom-
atic patients with corrected sinus node recovery time of more 
than 525 msec in electrophysiological studies.
Genetic analysis
Genomic DNA was isolated from peripheral blood lympho-
cytes using QIAamp DNA blood mini Kits (Qiagen, USA). The 
entire coding region (exons, 2–28) and exon-intron boundaries of 
SCN5A were amplified using specific oligonucleotide primers 
(9). PCR amplification performed in 25μL volume using conven-
tional 10× buffer, annealing temperature varied from 52 to 66 for 
different exon amplification. All amplicons were subjected to 
direct sequencing and then compared with the SCN5A sequence 
in the Ensemble database (reference SCN5A ENSG00000183873; 
www.ensembl.org).
Results
Fifty-three individuals, belonging to three families of LQTS, 
BrS, and SSS were studied. Twenty-eight members of the LQTS 
family, 16 of the BrS family, and 9 of the SSS family comprised 
our study population. The clinical characteristics of these 
patients (Table 1), clinical phenotypes of the symptomatic muta-
tion carriers (Table 2), and molecular characteristics of muta-
tions (Table 3) are shown.
p.Gln1507-Lys1508-Pro1509del mutation
The pedigree of the LQTS family is shown in Figure 4a. 
Sequencing results showed that in LQTS family 11 members car-
ried the p.Gln1507-Lys1508-Pro1509del mutation. These nine base 
pairs deletion (CAGAAGCCC) were located in exon 26 of SCN5A 
gene (Fig. 4b). Eleven patients with this mutation had prolonged 
QTc interval according to our definition; 1 had normal baseline 
ECG interval, 2 had implanted cardioverter defibrillator (ICD) due 
to aborted sudden cardiac death, and others were asymptomatic. 
Sixteen of them had normal ECG with no mutations.
p.Arg222Ter nonsense mutation
Pedigree of the BrS family is shown in Figure 5a. Sequencing 
results in BrS patients revealed p.Arg222Ter mutation. This non-
sense mutation (p.Arg222Ter) is located in exon 6 of the SCN5A 
gene (Fig. 5b). Two of the patients had ICD implant due to 
aborted sudden cardiac death.
Figure 1. LQTS ECG of 1 of our patients (individual II-7 of LQTS 
pedigree)
Figure 2. Type 1 ECG pattern of BrS (individual II-7 of BrS pedigree)
Figure 3. ECG of 1 of SSS patients (individual III-1 of SSS pedigree)
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p.Met1498Arg missense mutation
The pedigree of the SSS family is shown in Figure 6a. Five 
members of this family showed p.Met1498Arg missense 
mutation in exon 26 (Fig. 6b). Four of them had pacemaker 
implantation (DR-PPM Implantation) due to abnormal heart 
rhythms.
Discussion
In the present study, we analyzed SCN5A mutations in car-
diac arrhythmia syndromes associated with cardiac sodium 
channel (Nav1.5) dysfunction. Our study population included 53 
members belong to three families. Clinically, they were diag-
 Number of Number of positive  Male Male with SCN5A 
Probands patients mutation screened Age gender (n) mutation mutation
LQTa 28 11 30±2 13 4 Deletion in exon 26
BrSb 16 8 32±5 7 4 Nonsense mutation in exon 6
SSSc 9 5 25±3 7 4 Missense mutation in exon 26
aLongQT syndrome bBrugada syndrome cSick sinus syndrome
Table 1. Clinical characteristics of patients
 Age of first Triggering Cardiac arrest (LQT, BrS) Present Responding or Clinical 
Patient ID symptom factor (How many times) treatment not to treatment diagnosis Index
 LQTSc QTcd (ms)
II-1 35 Emotional stress - Beta blocker high dose No 455
II-2 40 Emotional stress - Beta blocker high dose No 460
II-4 40 Emotional stress Once ICDb Yes 490
II-6 33 Emotional stress - Beta blocker high dose No 480
II-7 36 Emotional stress - Beta blocker high dose No 484
II-9 40 Stress - Beta blocker high dose No 472
II-11 45 Crying Twice ICD Yes 602
III-2 10 Emotional stress - Beta blocker high dose No 463
III-3 15 Emotional stress - Beta blocker high dose No 452
III-8 20 Crying - Beta blocker high dose No 462
III-9 19 - - - - 450
 BrSa ST segment 
  elevation, mm
II-7 26 Running Twice ICD No 2.5
I-2 60 - - - - <2
II-1 47 - - - - <2
II-3 46 - - - - <2
II-5 45 - - - - <2
III-2 16 - - - - <2
III-3 12 - - - - <2
III-6 14 - - - - <2
 SSSe Bradycardia
I-2 42 Physical activity - Pacemaker implantation Yes Yes
II-3 25 Physical activity - Pacemaker implantation Yes Yes
III-1 29 Physical activity - Pacemaker implantation Yes Yes
III-2 22 Physical activity - Pacemaker implantation Yes Yes
II-2 50 - - - - No
III-3 20 - - - - No
aBrugada syndrome bImplantable cardioverter defibrillator cLong QT syndrome dCorrected QT interval eSick sinus syndrome
Table 2. Clinical characteristics of symptomatic mutation carriers and healthy mutation carriers
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nosed with LQTS, BrS, and SSS; all inherited in an autosomal 
dominant manner.
The mutation finding in LQTS patients was first reported by 
Keller et al. (10), is located in the DIII-DIV linker region of SCN5A 
gene, and plays an important role in fast sodium channel inactiva-
tion. Regarding BrS patients, p.Arg222Ter nonsense mutation was 
previously reported by Kapplinger et al. (11), is located in the DI-S4 
region of Nav1.5, and acts as a loss of function mutation. In the 
SSS family, we identified a novel c.4493T>G or p.M1498R missense 
mutation in DIII-DIV linker region of Nav1.5, which have not been 
previously reported.
All the three mutations are being reported for the first time in 
the Iranian population. In the LQTS family, 11 patients (39% 
cases) had the same mutation; however, one of the mutation 
carriers remained with no detectable abnormality in his ECG. The 
remaining 17 members had neither the mutation nor any abnor-
mal clinical findings. In the BrS family, eight patients were 
detected with p.Arg222Ter mutation; nevertheless, six of them 
had normal ECG in serial monitoring situations. The prevalence 
of the mutation in our limited study population emerged to be 
50%, which is more than previous studies (12-14). The detected 
mutation in SSS patients was located in the cytoplasmic region 
of Nav1.5 with a loss of function effect, i.e., attenuation of car-
diac Na current (15). Napolitano et al. (16) reported p.M1498T 
mutation in a patient who was clinically diagnosed with LQTS 
phenotype; however, our cases showed a phenotype compatible 
to SSS, on the basis of ECGs findings (Fig. 3). Out of the five 
patients, two individuals with positive mutations had normal ECG 
in serial monitoring situations and the rest of them (II-3, III-1,2) 
had pacemaker implantation.
Of the three detected mutations, c.4519_4528del CAGAAGCCC, 
c.664C>T, and c.4493T>G, two of them were located in exon 26 
(66% of all patients with positive mutations), indicating the 
hotspot nature of this exon for LQTS-3 and SSS syndromes in the 
Iranian population, which is in concordance with a previous 
report (17). The information gained here would be beneficial in 
planning genetic screening methods for Iranian patients with 
cardiac arrhythmia. Although we found that in the LQTS family 
all except 1 (III-9) patient with ECG findings of prolonged QTc 
having the mutation, the clinical penetrance of this kind of 
mutation should be further evaluated. Detection of BrS, LQTS-3-
associated, or SSS mutations can improve presymptomatic 
screening, enable better follow-up of asymptomatic patients, 
and facilitate choosing effective therapies earlier (17).
Gene name Nucleotide Change Aminoacid change Mutation Type Location Omima Reference (dbSNP)
SCN5A c.4519_4528del CAGAAGCCC p. Gln1507-Lys1508-Pro1509del (Hetero) Deletion (in frame) Exon 26 LQTS-3 Keller et al. (10)
SCN5A c.664C>T p.Arg222Ter (Hetero) Nonsense Exon 6 BrS Kapplinger et al. (11)
SCN5A c.4493T>G p.Met1498Arg (Hetero) Missense exon 26 SSS Novel
aOnline mendelian inheritance in man
Table 3. Molecular characteristics of gene mutation finding
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Figure 4. a, b. (a) The pedigree of the LQTS family. The filled symbols show symptomatic mutation carrier individuals, half-filled symbols 
asymptomatic mutation carriers with normal ECG, (b) sequencing results in-frame deletion mutation in LQTS patients (right) in comparison to 
normal control (left)
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Figure 5. a, b. (a) The pedigree of the BrS family. The filled symbols show asymptomatic mutation carriers, half-filled symbols asymptomatic 
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Study limitations
This study was performed including 3 Iranian families. In 
future, more families should be included and screened to find 
out the prevalence of the detected mutations in Iranian popula-
tion. Furthermore, this study was not aimed at conducting the 
functional analysis of these mutations.
Conclusion
In this study, which was conducted for the first time in Iran, 
we screened 53 cardiac arrhythmia patients for SCN5A muta-
tions and found 3 different mutations in 24 individuals diagnosed 
with different clinical syndromes. p.Gln1507-Lys1508-Pro1509del 
mutation, p.Arg222Ter nonsense mutation, and novel mutation 
p.Met1498Arg in LQTS, BrS, and SSS, respectively are reported 
for the first time in Iranian subjects. Information on the underly-
ing genetic defects of familial arrhythmias in Iranian patients 
would be extremely helpful in verifying clinical diagnosis, carri-
ers screening, and personalized therapy for the patients.
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